Relay Therapeutics Reports Strong Phase 2 Data for Zovegalisib in Vascular Anomalies, Demonstrating High Response Rates and Favorable Safety
RLAY has more than doubled off its 52-week low of $2.75.
Summary
Relay Therapeutics reported strong initial Phase 2 clinical data for zovegalisib in vascular anomalies, showing high volumetric response rates and significant symptomatic improvement with a favorable safety profile.
Key Events · Product Development and Regulatory · RLAY
-
Positive Phase 2 Efficacy Data
Zovegalisib achieved a 65% volumetric response rate (VRR) across doses in 20 response-evaluable patients with PIK3CA-driven vascular anomalies. 95% of patients experienced lesion reduction.
-
Significant Symptomatic Improvement
Clinical outcome assessments showed 89% of patients experienced investigator-reported clinical improvement (IGIC) and 79% patient-reported improvement (PGIC) at week 12.
-
Favorable Safety and Tolerability
The safety profile was generally as expected, with low-grade, manageable, and reversible treatment-related adverse events (TRAEs) at 100mg and 300mg BID. No patients discontinued treatment due to adverse events.
-
Clear Development Path Forward
Expansion cohorts for adults and adolescents have been opened at 400mg once daily (QD) and 300mg BID, with pediatric dose-finding ongoing, supporting a potential accelerated approval pathway.
Analysis · RLAY · Life Sciences
Relay Therapeutics announced compelling initial Phase 2 clinical data for zovegalisib in PIK3CA-driven vascular anomalies. The drug achieved a 65% volumetric response rate and significant symptomatic improvement in a patient population with limited treatment options. The favorable safety profile, particularly at lower doses, suggests potential for chronic use and a differentiated profile compared to existing therapies. This positive data significantly de-risks the program and supports a clear path towards potential accelerated approval, expanding the commercial opportunity for zovegalisib beyond its breast cancer indications.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 41% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLAY was trading at $13.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $2.75 to $17.32. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.